Search clinical trials for: Zibotentan (ZD4054)

Total 31 results

AstraZeneca

Completed

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

Prostate Cancer

Sweden, United States, Australia, France, United Kingdom, Poland, Finland, Netherlands, Norway, Belgium, Canada, Indonesia, Denmark, Switzerland
The Christie NHS Foundation Trust
AstraZeneca

Unknown

Window Study of ZD4054 in Metastatic Prostate Cancer

Prostate Cancer | Metastasis

United Kingdom
AstraZeneca

Completed

10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

China
AstraZeneca

Completed

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

Prostatic Neoplasms | Metastases, Neoplasm

United States
AstraZeneca

Completed

Food Effect Study of a Single Dose of ZD4054 (Zibotentan)

Healthy Volunteers

United Kingdom
University College, London
Medical Research Council

Completed

Zibotentan Better Renal Scleroderma Outcome Study (ZEBRA)

Chronic Kidney Disease | Scleroderma | Scleroderma Renal Crisis

United Kingdom
AstraZeneca
PRA Health Sciences

Completed

Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

Czech Republic
AstraZeneca

Completed

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases (ENTHUSE M1)

Prostate Cancer

Sweden, United States, Brazil, Czech Republic, France, Russian Federation, United Kingdom, Germany, China, Hungary, Poland, Finland, Netherlands, Mexico, Hong Kong, Australia, Belgium, Canada, Denmark, Portugal, South Africa, Korea... and more
AstraZeneca

Terminated

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer (ENTHUSE M0)

Prostate Cancer

Sweden, United States, Brazil, Czech Republic, France, Italy, Peru, Russian Federation, Spain, Turkey, United Kingdom, Germany, China, Hungary, Latvia, Poland, Romania, Japan, Finland, Norway, Canada, South Africa, Argentina, Australia, Belgiu... and more
AstraZeneca

Completed

Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.

Healthy

United States
Cardiff University

Withdrawn

Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer (PLANET)

Metastatic Breast Cancer

United Kingdom
University of Virginia
National Institutes of Health (NIH)

Completed

Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication

Peripheral Arterial Disease | Intermittent Claudication

United States
AstraZeneca

Completed

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

Prostate Cancer

United Kingdom, Germany, United States
AstraZeneca
ISTITUTO REGINA ELENA - CENTRO RICERCHE SPERIMENTALI

Terminated

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy

Italy, Germany
AstraZeneca

Completed

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer (ENTHUSE M1C)

Prostate Cancer

Sweden, United States, Brazil, France, Peru, Spain, United Kingdom, Germany, Poland, Romania, Finland, Canada, Argentina, Australia, South Africa, Czech Republic, India, Netherlands, Italy, Switzerland, Korea, Republic of, Hungary, ... and more
AstraZeneca

Completed

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study

Lung Cancer | Non Small Cell Lung Cancer

Bulgaria, Romania, Ukraine, France, Czech Republic
University of Wisconsin, Madison
AstraZeneca

Terminated

ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer

Prostate Cancer

United States
AstraZeneca

Completed

A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment

Renal Impairment | Hepatic Impairment

Bulgaria
AstraZeneca

Completed

Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval

Healthy

United Kingdom
NHS Greater Glasgow and Clyde
King's College London; University of Oxford; Royal Free Hospital NHS Foundation... and other collaborators

Completed

Precision Medicine With Zibotentan in Microvascular Angina (PRIZE)

Microvascular Angina

United Kingdom
AstraZeneca

Recruiting

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) (ZEAL)

Liver Cirrhosis

Denmark, Spain, Germany, United States, France, Australia, China, Belgium, Netherlands, Switzerland, Austria, United Kingdom, Taiwan, Canada, Czechia
Aarhus University Hospital
Rigshospitalet, Denmark

Terminated

A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer (DAPROCA-1)

Prostate Cancer | Metastasis

Denmark
AstraZeneca

Completed

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

Chronic Kidney Disease

United States
University Medical Center Groningen
AstraZeneca

Enrolling by invitation

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria (ZODIAC)

Chronic Kidney Diseases

Netherlands, Canada, United States, Denmark, United Kingdom
AstraZeneca

Completed

Drug Interaction Study to Asses Multiple Doses of ZD4054 (Zibotentan)

Healthy

Germany
AstraZeneca

Recruiting

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK (ZEAL UNLOCK)

Liver Cirrhosis

Italy, Japan, Germany, Belgium, Poland, Australia, United States, United Kingdom, Czechia, Slovakia
AstraZeneca
Parexel

Completed

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

Healthy Female Participants

United States
AstraZeneca

Recruiting

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

Chronic Kidney Disease With High Proteinuria

United Kingdom, Argentina, Italy, United States, Poland, Germany, Spain, Denmark, Sweden, France, China, Taiwan, Thailand, Vietnam, Brazil, Malaysia, Mexico, Philippines, Israel, Norway, Korea, Republic of, Canada, Japan, Turkey, Australia and more
AstraZeneca

Completed

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) (ZENITH-CKD)

Chronic Kidney Disease

United States, Italy, Spain, Brazil, Malaysia, Australia, South Africa, Hungary, Georgia, Japan, Bulgaria, Poland, Ukraine, Denmark, Argentina, Slovakia, Canada, Croatia, Netherlands
Genmab
BioNTech SE

Recruiting

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

Malignant Solid Tumor

Japan
Cardiff University

Completed

Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer (FOLFERA)

Colorectal Cancer

United Kingdom

Search clinical trials for: Zibotentan (ZD4054)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations